Tailored drug delivery vehicles for in vivo protection of analyte sensing compounds

Patent metadata

Field	Value
Publication number	US-2020375511-A1
Application number	US-202016887704-A
Country	US
Kind code	A1
Filing date	May 29, 2020
Priority date	May 29, 2019
Publication date	Dec 3, 2020
Grant date	—

Abstract

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and a drug eluting material having tailored elution properties that contains a drug that reduces deterioration of the analyte indicator, wherein the drug eluting material is incorporated in and/or in close proximity to the analyte indicator, and the drug eluting material is configured to release the drug according to a tailored elution profile.

First claim

What is claimed is:

1 . A sensor for measurement of an analyte in a medium within a living animal, the sensor comprising:
a sensor housing; an analyte indicator covering at least a portion of the sensor housing; and a drug eluting material having tailored elution properties comprising a drug that reduces deterioration of the analyte indicator, wherein the drug eluting material is incorporated in and/or in close proximity to the analyte indicator, and the drug eluting material is configured to release the drug according to a tailored elution profile.

2 . The sensor of claim 1 , wherein the sensor is implantable within a living animal.

3 . The sensor of claim 1 , wherein the drug eluting material comprises at least one drug eluting polymer matrix covering at least a portion of the sensor housing, and the drug is dispersed within the drug eluting polymer matrix.

4 . The sensor of claim 1 , wherein the tailored elution profile includes a release rate that is between a minimum therapeutic release rate and a toxic release rate of the drug.

5 . The sensor of claim 1 , wherein the drug eluting material comprises 0.1-60% w/w of an additive.

6 . The sensor of claim 1 , wherein the drug eluting material comprises an additive selected from: a hydroxypropyl methylcellulose; a polyalkylene glycol; a polyalkylene oxide; a polyether or a copolymer of polyethers; di-block, tri-block, grafted, post-functionalized polyether-siloxane copolymers; copolymers thereof, and combinations thereof.

7 . The sensor of claim 1 , wherein the drug eluting material comprises an additive selected from: a hydroxypropyl methylcellulose; polyethylene glycol; polypropylene glycol; polyethylene oxide; polypropylene oxide; copolymers thereof, and combinations thereof.

8 . The sensor of claim 1 , wherein the drug eluting material comprises a silicone-based matrix and 1 wt. % to 60 wt. % of said drug.

9 . The sensor of claim 1 , wherein the drug eluting material comprises an organic-based matrix and 1 wt. % to 75 wt. % of said drug.

10 . The sensor of claim 1 , wherein the drug eluting material is selected from an organic hydrogel-based matrix containing polyethers, acrylics, silicones including medical grade silicones, derivatives thereof, and combinations thereof.

11 . The sensor of claim 1 , wherein the drug eluting material comprises liquid silicone rubber, silicone adhesive, silicone foam, silicone dispersion, and combinations thereof.

12 . The sensor of claim 1 , wherein the drug eluting material comprises one or more catalytic additives that modify the cure rate of the drug eluting material.

13 . The sensor of claim 1 , wherein the drug eluting material is injection molded, cured using a heat gun, cured at room temperature, or cured at 30-40° C.

14 . The sensor of claim 1 , wherein the drug eluting material comprises one or more of glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and antioxidants.

15 . The sensor of claim 1 , wherein the drug eluting material is configured to elute the drug to interact or react with a degradative species without compromising signal integrity or performance of the sensor device, and the degradative species is hydrogen peroxide, a reactive oxygen species, a reactive nitrogen species, or a free radical.

16 . The sensor of claim 1 , wherein the drug eluting material has a preformed shape.

17 . The sensor of claim 16 , wherein the preformed shape is a ring, a sleeve, a conformal shell, a cylinder, or a monolith.

18 . The sensor of claim 1 , wherein the drug eluting material comprises acetylsalicylic acid.

19 . The sensor of claim 1 , wherein the drug eluting material comprises isobutylphenylpropanoic acid.

20 . The sensor of claim 1 , wherein the drug is dexamethasone, triamcinolone, betamethasone, methylprednisolone, beclometasone, fludrocortisone, a derivative thereof, an analog thereof, or a combination of two or more thereof.

21 . The sensor of claim 1 , wherein the analyte indicator is a graft including indicator molecules.

22 . The sensor of claim 1 , further comprising a layer of a catalyst capable of converting hydrogen peroxide into water and oxygen on at least a portion of the analyte indicator.

23 . The sensor of claim 1 , further comprising a membrane covering at least a portion of the analyte indicator.

24 . The sensor of claim 23 , wherein the membrane is a porous, opaque diffusion membrane.

25 . A method of fabricating a sensor for measurement of an analyte in a medium within a living animal, the method comprising:
applying an analyte indicator to a sensor housing of the sensor such that the applied analyte indicator covers at least a portion of the sensor housing, and applying a drug eluting material having tailored elution properties comprising a drug that reduces deterioration of the analyte indicator such that the applied drug eluting material is incorporated to the sensor in and/or in close proximity to the analyte indicator, wherein the drug eluting material is configured to release the drug according to a tailored elution profile and reduce deterioration of the analyte indicator.

Assignees

• Senseonics Inc

Inventors

• Huffstetler Philip
• Sandoval Wendolyn
• Lorenz Carrie R
• Velvadapu Venkata
• Chatterjee Joon

Classifications

• A61B5/01

  Measuring temperature of body parts {; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue} (clinical contact thermometers G01K13/20) · CPC title

• A61B5/14546

  for measuring analytes not otherwise provided for, e.g. ions, cytochromes · CPC title

• A61B5/1451

  for interstitial fluid · CPC title

• A61B5/1459

  invasive, e.g. introduced into the body by a catheter · CPC title

• A61B5/14503

  invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors (A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence) · CPC title